Figure 1.
Schematic representation of the PI3K/mTOR pathway.
Table 1.
Characteristics of included studies.
Table 2.
Prevalence and analyses of the molecular alterations of the PI3K/mTOR/AKT pathway.
Figure 2.
Odds ratio (OR) for 5-year overall survival (OS) in all studies.
Forest plots of odds ratios for overall survival at 5 years based on activation of the PI3K/mTOR/AKT pathway. Odds ratios for each trial are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval. The diamonds represent the estimated pooled effect based for each cohort individually (labeled subtotal) and for all cohorts together (labeled total).
Figure 3.
Odds ratio (OR) for 5-year overall survival (OS) according to the expression of different components of the PI3K/mTOR pathway (group subtype).
Forest plots of odds ratios for overall survival at 5 years split by subgroups defined by type of activation of the PI3K/mTOR/AKT pathway. Odds ratios for each trial are represented by the squares, the size of the square represents the weight of the trial in the meta-analysis, and the horizontal line crossing the square represents the 95% confidence interval. The diamonds represent the estimated pooled effect based for each cohort individually (labeled subtotal) and for all cohorts together (labeled total).